Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Introduces Integrated Backend and Global Payment Solutions for Games, With Founding Partner AccelByte19.8.2026 16:00:00 EEST | Press release
Xsolla, a global video game commerce company, today introduced integrated backend solutions for game developers through a founding partnership with AccelByte, a fully managed extensible games backend platform, and opened a closed testing program for a combined solution that pairs AccelByte Gaming Services (AGS) with Xsolla's global payments and monetization tools. Select developers can now apply for early access and help shape the integration ahead of its broader launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819624666/en/ Graphic: Xsolla As studios scale live games across PC, mobile, console, and the web, managing player persistence, gaming backend, and global transactions adds cost and slows launches. Through the founding partnership with AccelByte, Xsolla brings AccelByte's backend services together with its own payments and monetization in one integrated stack, so studios no longer need to stitch separate solu
Corpay Cross-Border Named the Official FX Partner of European T20 Premier League19.8.2026 15:30:00 EEST | Press release
Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with the European T20 Premier League (“ETPL”), a new franchise-based tournament sanctioned by the International Cricket Council, created to establish Europe as a dynamic force in the global T20 landscape. Under the agreement, Corpay becomes EPTL’s exclusive and Official Foreign Exchange (FX) Partner, along with being an Official Partner. As the EPTL’s exclusive foreign exchange partner, Corpay Cross-Border will provide the league with comprehensive FX risk management solutions to help mitigate foreign exchange exposure arising from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable the EPTL to streamline global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclusive and official FX partner of the European T20 Premier League,” said Brad Loder
Mary Kay Accelerates Beauty Innovation and Digital Transformation19.8.2026 15:00:00 EEST | Press release
Mary Kay Inc. (“Mary Kay”), global iconic leader in beauty and entrepreneurship, announced today transformative business milestones, inviting the next generation to engage with a modernized Mary Kay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819989520/en/ Ryan Rogers, Chief Executive Officer of Mary Kay Inc. (Image Credit: Mary Kay Inc.) Statement fromRyan Rogers, Chief Executive Officer of Mary Kay: “We are re-defining the moment for Mary Kay. We are investing in technology and research to create seamless digital experiences while preserving the personal connections and sense of community that have always set Mary Kay apart. From the launch of Mary Kay My Shop to next-generation product innovation and purpose-driven impact, each milestone reflects the momentum behind our transformation. Building on more than 60 years of entrepreneurial legacy, we are reimagining how consumers engage with Mary Kay, meeting them where
Xceedance Appoints Insurance and Technology Executive Adrian Spieler to Board of Directors19.8.2026 15:00:00 EEST | Press release
Xceedance, a global provider of technology-driven business solutions for the insurance industry, today announced the appointment of Adrian Spieler to its Board of Directors, effective immediately. Spieler brings more than 30 years of experience across reinsurance, insurance, and asset management to the Xceedance board. He has served as Chief Operating Officer at Convex Insurance, a leading specialty insurer and reinsurer, since its launch in 2019. Before Convex, he spent 17 years at Swiss Re in a series of senior leadership positions, and later served as Group Chief Administrative Officer at Catlin and as Chief Enterprise Operations Officer and Chief Platform Officer, Insurance, at XL Catlin. As a member of the Xceedance Board of Directors, he will provide strategic guidance, set organizational goals, and measure success as the organization continues its high-growth trajectory. “Technology-enabled transformation is reshaping the insurance and reinsurance industries,” said Spieler, “and
Oscilloquartz expands US aerospace, defense and government presence to address rising demand for resilient PNT19.8.2026 15:00:00 EEST | Press release
Oscilloquartz today announced an expansion of its US aerospace, defense and government presence through agreements with six specialized sales representative firms: ProTEQ Solutions, Southern Marketing Associates (SMA), Testech, TMS Sales, Contech Marketing Associates and Ward/Davis Associates. These partnerships expand regional coverage and deepen customer engagement, addressing growing demand for resilient timing and synchronization in mission-critical applications. “Demand for resilient timing and assured PNT continues to accelerate across aerospace, defense and government applications,” said Tim Weathers, president of Southern Marketing Associates. “Oscilloquartz offers a highly differentiated portfolio of synchronization technologies designed for operation in contested and GNSS-denied environments. We see strong opportunities to help customers strengthen operational resilience and are excited to support the company’s continued expansion in the US market.” The newly appointed repres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom